Skip to main content
. 2021 Feb 26;42(7):940–950. doi: 10.1093/carcin/bgab017

Figure 5.

Figure 5.

DPYD expression is associated with poor prognosis in human PDAC. Immunohistochemical staining of DPYD in a PDAC tissue microarray (n = 73) stratified into four categories (0; none, 1+; weak, 2+; moderate, 3+; strong) and coded as DPYD low (0, 1+, 2+, n =50) and high expression (3+, n = 23) (A). Three-year overall survival (OS) (B) and 3-year recurrence-free survival (RFS) (C) of PDAC patients with low DPYD (n = 50) or high DPYD expression (n = 23) *P = 0.045 between low and high DPYD expression groups. DPYD expression score and Ki-67 labeling index (Spearman rho = 0.445, P < 0.05) (D). Three-year OS of PDAC patients with S-1 adjuvant therapy (n = 45) including high DPYD (n = 15) and low DPYD expression groups (n = 30) *P = 0.018 between low and high DPYD expressors (E).